Key Highlights

● Nasdaq's Hearings Panel upheld a delisting decision, and trading was suspended from the opening of business on March 7, 2024.

● The panel cited closing prices below $1.00 for thirty consecutive trading days and equity below the required $2.5 million.

● Revenue for the twelve months to December 31, 2023 was $39.11 million against a net loss of $53.52 million.

● Neptune sold its cannabis assets for C$5.15 million in October 2023 to become a pure-play consumer packaged goods business.

Neptune Wellness Solutions Inc. (OTC:NEPTF) is a consumer packaged goods company whose shares now appear on the over-the-counter market, also written NEPT.F. The listing history is the main reason investors encounter it in this form. Nasdaq's Hearings Panel upheld a delisting decision, and the company announced on March 6, 2024 that trading on Nasdaq would be suspended from the opening of business on March 7, 2024.

The most recent verifiable information is therefore old. The newest financial data covers the twelve months to December 31, 2023, so any picture of the business is historical.

Brands and sector

Neptune operates in consumer health and wellness. Market data providers describe a portfolio that includes omega-3 fish oils and softgel solutions under the Biodroga name, vegan multi-omega gummies under Forest Remedies and organic baby food under the Sprout brands. Market data lists Nosh and Nurturme among its food brands and gives its headquarters as Laval, Quebec, with 104 employees and a founding year of 1998.

In October 2023, the company sold its cannabis assets for C$5.15 million to become a pure-play consumer packaged goods business. A non-binding letter of intent to acquire Datasys Group for roughly $110 million was announced in November 2023, but it was never completed.

Why Nasdaq removed the shares

According to market data, the Panel's decision cited two deficiencies. The shares had closed below the $1.00 minimum bid price for thirty consecutive trading days, and stockholders' equity had fallen below the required $2.5 million. The hearing took place on February 29, 2024, the written decision followed on March 5, and the company said it was pursuing quotation on the OTCQB Venture Market. At the time the stock was priced at about $0.20.

Separately, Neptune announced a voluntary delisting from the Toronto Stock Exchange, which narrowed its public venues further. The OTC tier at which the shares currently trade is not verified.

Financial context

Over the twelve months to December 31, 2023, market data reports revenue of $39.11 million and a net loss of $53.52 million. Gross profit was negative at about $0.76 million. Market data shows total debt of about $28.1 million against total assets of about $23 million. For fiscal 2022, revenue had been $48.8 million, a rise of 37.9% year on year, as reported, so sales have since fallen sharply.

Aggregator pages show a share price near $0.000001 and a market capitalisation of only a few dollars. These values are almost certainly distorted by illiquid or stale quotations and should not be read as a reliable measure of worth.

Stale Filings Leave Neptune's Solvency Unclear

The core risk is information. Market data flags that shares are highly illiquid and that the latest financial reports are more than a year old. A company with losses larger than its sales, debt that exceeds its assets and no current disclosures leaves outsiders unable to judge solvency. Brand-led consumer businesses also depend on retail relationships and working capital, both of which weaken when credit is scarce.

Newly filed annual or interim statements, an auditor's opinion, any restructuring, insolvency or asset-sale announcement, and clarification of the quotation tier and any trading restrictions would show where the business stands. The factual summary is for now a consumer health company that lost its Nasdaq listing in March 2024 and has little current public disclosure.